Insulin aspart biosimilar (Biocon/Mylan)

门冬胰岛素生物类似药 (Biocon/Mylan)

Report date: 2025/07/16 10:22:46

Base Information

Drug NameInsulin aspart biosimilar (Biocon/Mylan)
Drug Alias Name天冬胰岛素生物仿制药 (Biocon/Mylan)门冬胰岛素生物仿制药 (Biocon/Mylan)KIRSTYMYL-1601D
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/02/05
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiocon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocon Biologics IncBiosimilar Collaborations Ireland Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB05A10AD05
Related LinksN/A